- In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported citing the Washington University School of Medicine.
- The latest study included three of the four variants that have been designated "variants of concern" by the WHO.
- The FDA in April revoked the emergency use authorization of Eli Lilly And Co's LLY single antibody therapy, bamlanivimab, amid resistance due to the variants.
- The researchers evaluated the FDA authorized combination therapies made by Regeneron Pharmaceuticals Inc REGN, Eli Lilly, and single antibody therapy, sotrovimab by Vir Biotechnology Inc VIR and GlaxoSmithKline Plc GSK.
- They also assessed the antibodies in clinical trials by AbbVie Inc ABBV, Vir, and AstraZeneca Plc AZN.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
